CD274 and neoplasm: Further, evaluation of PD-L1 as a predictive biomarker for response to pembrolizumab across tumor types revealed that PD-L1 expression was only predictive in 28.8% of FDA approvals, indicating the imprecise nature of utilizing PD-L1 as a predictive biomarker (48).